CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals or presented at major oncology conferences.
  • Recall ongoing clinical trials in select hematologic cancers and solid tumors, and as appropriate, refer patients for participation.
  • Incorporate individual preferences, tumor biomarkers, single and multigene signatures and other treatment-related factors in personalizing therapy for patients with cancer.
  • Educate patients with hematologic cancers or solid tumors about the benefits and risks of novel therapeutic agents and strategies.
  • Apply an awareness of new data sets and the perspectives of tumor-specific clinical investigators to refine or validate treatment algorithms.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice. 

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 6 (audio) and 5.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide sets, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/AON24/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/AON24/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/AON24/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/AON24.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Harry Paul Erba, MD, PhD
  Director, Leukemia Program
  Professor in the Department of Medicine
  Member of the Duke Cancer Institute
  Duke University School of Medicine
  Durham, North Carolina
  
  Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, Gilead Sciences Inc, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Pfizer Inc, Protagonist Therapeutics, Rigel Pharmaceuticals Inc, Schrödinger, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Aptose Biosciences Inc, Ascentage Pharma, Daiichi Sankyo Inc, Forma Therapeutics, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Kura Oncology, MacroGenics Inc, Novartis, Oryzon, PTC Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc; Independent Review Committee Chair: AbbVie Inc; Speakers Bureaus: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol Myers Squibb, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Steering Committees: Bristol Myers Squibb (Chair), Daiichi Sankyo Inc (Co-Chair), GlycoMimetics Inc; Nonrelevant Financial Relationship: Fortrea.
  
  Edward B Garon, MD, MS
  Professor
  Director, Thoracic Oncology Program
  Director, Signal Transduction and Therapeutics Research Program
  David Geffen School of Medicine at UCLA
  Jonsson Comprehensive Cancer Center
  Los Angeles, California
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, Arcus Biosciences, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Atreca, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, EMD Serono Inc, Gilead Sciences Inc, Hookipa Pharma Inc, I-Mab Biopharma, LianBio, Lilly, Merck, Merus, Novartis, Nuvalent, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Sensei Biotherapeutics, Strata Oncology, Sumitomo Dainippon Pharma Oncology Inc, Summit Therapeutics, Synthekine; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Sponsored Independent Medical Education: Daiichi Sankyo Inc; Travel: A2 Bio, Novartis.
  
  Daneng Li, MD
  Associate Professor
  Department of Medical Oncology and Therapeutics Research
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Coherus BioSciences, Eisai Inc, Elevar Therapeutics, Exelixis Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Merck, Sumitomo Dainippon Pharma Oncology Inc, TransThera, TriSalus Life Sciences; Contracted Research: AstraZeneca Pharmaceuticals LP.
  
  Christopher Lieu, MD
  Professor of Medicine
  Associate Director for Clinical Research
  Co-Director, GI Medical Oncology
  University of Colorado Cancer Center
  Aurora, Colorado
  
  No relevant conflicts of interest to disclose.
  
  Kathleen N Moore, MD, MS
  Deputy Director
  Associate Director, Clinical Research
  Virginia Kerley Cade Chair in Developmental Therapeutics
  Co-Director, Cancer Therapeutics Program
  Stephenson Cancer Center at the University of Oklahoma HSC
  Associate Director, GOG Partners
  Board of Directors, GOG Foundation
  Oklahoma City, Oklahoma
  
  Advisory Committees: Aadi Bioscience, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Caris Life Sciences, Clovis Oncology, Duality Biologics, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Janssen Biotech Inc, Lilly, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Panavance Therapeutics, Regeneron Pharmaceuticals Inc, VBL Therapeutics, Verastem Inc, Zentalis Pharmaceuticals; Consulting Agreements: Aadi Bioscience, Caris Life Sciences, Duality Biologics, Eisai Inc, Mersana Therapeutics Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Genentech, a member of the Roche Group, GSK, Lilly, PTC Therapeutics.
  
  Stephen T Oh, MD, PhD
  Associate Professor of Medicine
  Co-Chief, Division of Hematology
  Washington University School of Medicine
  St Louis, Missouri
  
  Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation, Morphic Therapeutic, MorphoSys, Protagonist Therapeutics; Stock Options — Private Company: Harmonic Discovery.
  
  Moderator
  Stephen "Fred" Divers, MD
  Chief Medical Officer
  American Oncology Network
  Hot Springs, Arkansas
  
  Advisory Committee: Daiichi Sankyo Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Geron Corporation, GSK, Incyte Corporation, Natera Inc, Pfizer Inc and Genmab US Inc, and Taiho Oncology Inc.
  
  Release date: December 2024
  Expiration date: December 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.